ProMIS Neurosciences (PMN) Net Income (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Net Income came in at -$8.7 million in Q1 2026, down 16.84% YoY from -$10.5 million in Q1 2025, and up 83.18% on a QoQ basis from -$51.8 million in Q4 2025.
ProMIS Neurosciences (PMN) Net Income (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 6 years of Net Income data on file, last reported at -$8.7 million in Q1 2026.
- Quarterly Net Income fell 16.84% year-over-year to -$8.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$82.5 million (down 298.5% YoY) and the FY2025 annual result came in at -$81.2 million, down 66.71% from the prior year.
- Net Income grew to -$8.7 million in Q1 2026, from -$51.8 million in the prior quarter.
- In the past five years, Net Income ranged from a high of -$2.6 million in Q3 2023 to a low of -$51.8 million in Q4 2025.
- A 5-year average of -$8.5 million and a median of -$5.0 million in 2022 frame the typical range for Net Income.
- Annual changes were most pronounced in 2023 — Net Income soared 57.2% — and 2025, when it slumped 763.16%.
- Tracing PMN's Net Income over 5 years: stood at -$8.5 million in 2022, then surged by 53.64% to -$4.0 million in 2023, then slumped by 51.91% to -$6.0 million in 2024, then tumbled by 763.16% to -$51.8 million in 2025, then jumped by 83.18% to -$8.7 million in 2026.
- The last three Net Income figures came in at -$8.7 million (Q1 2026), -$51.8 million (Q4 2025), and -$11.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 81.49 Mn |
| 10 | ProMIS Neurosciences | 135.44 Mn | 81.98 Mn | - | -12.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.40 Mn |
| Mar 31, 2026 | -8.72 Mn |
| Dec 31, 2025 | -51.81 Mn |
| Sep 30, 2025 | -11.75 Mn |
| Jun 30, 2025 | -10.18 Mn |
| Mar 31, 2025 | -7.46 Mn |
| Dec 31, 2024 | -6.00 Mn |
| Sep 30, 2024 | -4.45 Mn |
| Jun 30, 2024 | -2.78 Mn |
| Mar 31, 2024 | -3.83 Mn |
| Dec 31, 2023 | -3.95 Mn |
| Sep 30, 2023 | -2.59 Mn |
| Jun 30, 2023 | -2.95 Mn |
| Mar 31, 2023 | -4.97 Mn |
| Dec 31, 2022 | -8.52 Mn |
| Sep 30, 2022 | -6.06 Mn |
| Jun 30, 2022 | -5.00 Mn |
| Mar 31, 2022 | -4.09 Mn |
| Dec 31, 2021 | -4.69 Mn |
| Sep 30, 2021 | -2.21 Mn |